Skip to content
Buy This GLP
← Research
Safety

Compounded tirzepatide and B12 react with each other

Testing found a new impurity across compounded tirzepatide-B12 products. It forms from the two ingredients themselves, so a more careful pharmacy would not prevent it.

Wesley Jenkins6 min read
Not contamination — a reactiontirzepatide+certain B12analogsa new impurity, at substantial levelsClinical effect: unknown. Nobody has tested it.

Combining a GLP-1 drug with vitamin B12 is one of the most common things compounders do, and sellers ranked on this desk publish products under names like Tirzepatide/B12 on their own price tables. A group tested samples of those combinations obtained from various US sources and found something nobody had described before [1]. The market that produces them is described in what the secret-shopper study found.

The finding is a previously unidentified impurity, present at substantial levels and widespread across the samples tested. What makes it different from the usual compounding story is its origin: it forms from a chemical reaction between tirzepatide and certain analogs of B12.

What the paper does not say matters as much as what it does. The clinical effect of this impurity is unknown — nobody has tested whether it does anything to a person, and no patient harm is reported or alleged anywhere in the work. Nothing here is a reason to stop taking something mid-course, and it is not a finding about safety in the sense of measured harm.

One question the abstract leaves open should be named rather than assumed. Papers testing compounded copies of a branded drug are sometimes written by people who work for the company that makes the original, which was true of the semaglutide impurity testing covered in tested by the company that makes the original. This paper's abstract does not state its funding, so the honest position is that the question is open — not that it has been answered either way. The analytical finding stands or falls on whether other laboratories reproduce it.

For someone choosing between listings, the practical consequence is narrow and real. A combination product carries whatever the combination does, and the B12 in these formulations is there largely as a marketing differentiator rather than because a deficiency was measured. A plain single-ingredient compound avoids this particular question entirely, and the price difference between formulations is usually small — a comparison the desk sets out in what a GLP-1 actually costs and sellers publishing two prices.

Frequently asked

Is compounded tirzepatide with B12 dangerous?
Unknown. The testing found an impurity formed by the two ingredients reacting, but nobody has established what that impurity does in a person, and the paper reports no patient harm.
Would a better compounding pharmacy avoid this?
Apparently not, if the mechanism is right. The impurity arises from a reaction between tirzepatide and certain B12 analogs, which makes it a property of the combination rather than of a facility's cleanliness.
Why is B12 in there at all?
Mostly as a product differentiator. These combinations are marketed as personalized formulations, and in most cases no deficiency was measured before the B12 was added.

Sources

  1. [1] Jordan B, Arbogast L, Clemens M, Huang L, Snyder M (2026). A novel, widespread impurity in mass-compounded tirzepatide/B12 products: potential patient safety implications Expert Opinion on Drug Safety. PMID 42010938

More in Safety